Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Sickle cell disease is a group of disorders that affects hemoglobin, and the molecule in red blood cells that delivers oxygen to cells throughout the human body. People with this disease have atypical hemoglobin molecules called hemoglobin S, which can distort the biconcave shape of red blood cells into a sickle, or crescent, shape. The sickle cell anemia is an inherited red blood cell disorder, a condition in which the red blood cells are very weak to carry oxygen throughout the human body. The Beta thalassemia results in the decrease in the synthesis or complete absence of the beta globin chains of hemoglobin. In sickle hemoglobin C the red blood cells are stickier than usual, and thus may clog up the small blood vessels in the bones and other parts of the human body. Sickle beta-zero thalassemia is another type of sickle cell disease which involves globin gene and is similar to sickle cell anemia.
The North America sickle cell disease market is estimated to be valued at US$ 770.5 million in 2021 and is expected to exhibit a CAGR of 16.2% over the forecast period (2021-2028).
Figure 1. North America Sickle Cell Disease Market Share (%) in Terms of Value, By Country, 2021
Fund raising by key players for boosting research and development for the treatment of sickle cell disease is expected to drive the market growth over the forecast period.
The key players in North America are focusing on fund raising for boosting research and development for the treatment of sickle cell disease. For instance, in March 2019, Imara, Inc., a medical device company, announced that the company raised funds which accounted for US$ 63 million from Series B funding round held by OrbiMed Advisors and Arix Bioscience plc. The fund raised by the company would be utilized for the research and development of IMR-687 which is a phosphodiesterase 9 (PDE9) inhibitor in clinical development as a once a day, oral therapy for the treatment of sickle cell disease (SCD) and thalassemia, and to expand the company’s product pipeline.
North America Sickle Cell Disease Market Report Coverage
||Market Size in 2021:
||US$ 770.5 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 2,200.5 Mn
- North America: U.S. and Canada
- By Disease Type: Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease
- By Drug Type: Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
- Increasing product approvals/ launches for treatment of sickle cell disease (SCD)
- Fund raising by key players for treatment & awareness of SCD
|Restraints & Challenges:
- Major side effects of pharmacological treatments such as hydroxyurea
Figure 2. North America Sickle Cell Disease Market Share (%), by Drug Type, 2021
North America Sickle Cell Disease Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The Coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, Coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the sickle cell disease medications businesses of various companies, across the regions such as North America, as COVID 19 pandemic has led to unprecedented lockdown in several regions and as well in North America. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Furthermore, various research institutes and academic institutes focusing on performing clinical trial on effect of COVID-19 on individuals suffering from sickle cell disease. For instance, in June 2020, the U.S. National Human Genome Research Institute (NHGRI) initiated clinical trial on study extent and impact of life changes induced by the COVID-19 pandemic on people living with sickle cell disorders (SCD) in the U.S. The study states that adults living with SCD will be adversely impacted by COVID-19 in terms of stress, anxiety, coping, and sleep. Individuals living with SCD will have higher fear, isolation, anxiety and stress, if they have higher clinical severity. Thus, the impact of Coronavirus (COVID-19) pandemic is expected to limit the growth of the North America sickle cell disease market during the forecast period.
North America Sickle Cell Disease Market: Restraint
Major side effects of the pharmacology treatments such as hydroxyurea is expected to hinder the growth of the North America sickle cell disease market. For instance, according to the report published by Starpearls, an authenticated healthcare library throughout the world and articles reviewed by PubMed (MEDLINE database of references and abstracts on life sciences and biomedical topics), various major side effects of hydroxyurea on the long-term treatment in patients suffering from sickle cell disease such as gastrointestinal, dermatological, reproductive, and pulmonary effects restrain the market growth.
Major players operating in the North America sickle cell disease market include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.